Search
Scarlet red
go.drugbank.com/drugs/DB19136ApprovedWithdrawnScarlet red is under investigation in clinical trial NCT00591916 (New Treatment for Donor Sites).
Categories: Compounds used in a research, industrial, or household settingAdavosertib
go.drugbank.com/drugs/DB11740InvestigationalMK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.
MK-0533
go.drugbank.com/drugs/DB15242InvestigationalMK-0533 is under investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)).
ATB-346
go.drugbank.com/drugs/DB15377InvestigationalATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).
Vecabrutinib
go.drugbank.com/drugs/DB16657InvestigationalVecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).
Levosalbutamol
go.drugbank.com/drugs/DB13139ApprovedLevosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Volixibat
go.drugbank.com/drugs/DB13914Investigationalfor NASH[L1662]. … If approved for use, it will be the first available agent for the treatment of NASH.
Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigational[A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019. … Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.
Diloxanide
go.drugbank.com/drugs/DB08792ExperimentalAlthough it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.
Perflutren
go.drugbank.com/drugs/DB00556ApprovedInvestigationalPerflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane … During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Categories: Compounds used in a research, industrial, or household setting